We are a global specialty and branded pharmaceutical company, improving the health of patients across the world through our high quality and affordable medicines. Active at every stage of the value chain, we are uniquely diversified by geography, product and manufacturing capability.

Our business segmentsWe focus on marketing and manufacturing a broad range of post-patent, branded medicines and domestic brands covering both hospital and consumer markets through our key business segments.
ABOUT ASPEN
Commercial Pharmaceuticals

46%
of total revenue


Regional Brands- a widely diverse range of trusted medicines with strong domestic or regional presence.

28%
of total revenue


Sterile Focus Brands- comprising our branded products in anaesthetics and thrombosis therapy areas.

Manufacturing26%
of total revenue

Internal and third party supply of chemical and biochemical APIs and finished dose form ("FDF") pharmaceuticals.

Our global presenceHeadquartered in South Africa, we have a strong presence in both emerging and developed markets.

65%
of Commercial Pharmaceuticals revenue from emerging markets

https://www.aspenpharma.com/global-presence/

Our manufacturing capabilitiesOur manufacturing capabilities span a wide variety of product types including steriles, oral solid dose, liquids, semi-solids, biologicals and active pharmaceutical ingredients ("APIs"). Our manufacturing sites hold international approvals from some of the most stringent global regulatory agencies.

7
Active pharmaceutical ingredient facilities

23
Facilities

16
Finished dose form facilities

https://www.aspenpharma.com/manufacturing-capabilities/

Leadership reviews

CHAIRMAN'S REVIEWGROUP CHIEF EXECUTIVE'S REVIEWDEPUTY GROUP CHIEF EXECUTIVE'S FINANCIAL REVIEWChairman's reviewAspen's long-term sustainability and success will be measured by the value we deliver to society. As a manufacturer and distributor of essential medicines, Aspen is uniquely placed to make a meaningful contribution to the global goals of increasing access to high quality, affordable medicines and reducing patient inequality.

Kuseni Dlamini
Chairman

> View Chairman's review
Group Chief Executive's reviewIn spite of the significant challenges faced, this has been a defining year for Aspen. We have delivered both a strong organic performance and also a reshaped Group in line with our stated strategic intent. However, it has also been a year which has vindicated our single-minded focus on building a sterile platform and the related relevance of the Aspen portfolio and manufacturing capabilities to patients in need globally.

Stephen Saad
Group Chief Executive

> View Group Chief Executive's review
Deputy Group Chief Executive's financial reviewThe Group has delivered double-digit organic revenue growth and sustained strong operating cash flows demonstrating agility and resilience during a period of difficult trading conditions. As we deliver on our strategic plan, our strong balance sheet provides optionality to invest in future growth opportunities.

Gus Attridge
Deputy Group Chief Executive

> View Deputy Group Chief Executive's financial review
Our value creation process
Our value creation process, which is driven by our purpose and vision, is an integral part of our business strategy. We leverage and apply our stock of capitals to deliver on our strategic objectives and optimise value for our stakeholders.
VALUE CREATION PROCESS
Our approach to Sustainability
We are committed to creating value for all of our stakeholders in a manner that is responsible, transparent, and that respects the rights of all. We recognise that to achieve long-term success, we need to deliver our business strategy in a way that creates value not only to Aspen and our shareholders, but also to society and the planet.
SUSTAINABILITY APPROACH
Business segment overviews
As we adapt to our constantly evolving environment, our strategy is focused on delivering on our purpose and creating longterm value for our shareholders and the society in which we operate.
STERILE FOCUS BRANDSREGIONAL BRANDSMANUFACTURING
Creating value through our capitals
creation, we leverage our six capitals and unique value drivers to provide high quality, affordable medicines in a responsible and sustainable way.
VALUE THROUGH CAPITALS

Attachments

Disclaimer

Aspen Pharmacare Holdings Ltd. published this content on 09 October 2023 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 09 October 2023 10:25:22 UTC.